Percutaneous renal denervation in the management of hypertension: Chinese expert scientific statement

作者：Yueping Li, Chengzhi Lu, Xiongjing Jiang, Jing Yu, Ma Wei, Jialu Hu, Yi Zhang, Yujie Zhou, Ningling Sun, Yong Huo, Junbo Ge, Xiaoping Chen, Yundai Chen, Hong Jiang, Xiangqing Kong, Nanfang Li, Likun Ma, Liguo Shen, Xi Su, Jie Wang, Jingfeng Wang, Yuehui Yin, Yuqing Zhang · 发表于：Cardiology Plus · 年份：2024 · DOI：10.1097/cp9.0000000000000083 · 被引用次数：7 · 研究领域：Blood Pressure and Hypertension Studies、Chronic Kidney Disease and Diabetes、Sodium Intake and Health

Hypertension constitutes a critical risk factor for cardio-cerebrovascular disease. Despite the effectiveness of lifestyle adjustments and medications in blood pressure (BP) management, the hypertension control rates remain inadequate. Percutaneous renal denervation (RDN) has emerged as a forward-looking and evidence-supported interventional modality for the improvement of BP regulation and enhancement of hypertension control. Comprehensive evidence from randomized, sham-controlled clinical trials supports the sustained the efficacy and satisfactory safety profile of RDN in lowing BP. This scientific statement, endorsed by Chinese authorities, aims to provide a comprehensive overview of global and national clinical evidence on RDN. It seeks to highlight the therapeutic advancements of RDN, articulate expert consensus and recommendations for its utilization in hypertension management. Through the promotion of structured, safe, and standardized incorporation of RDN into clinical practice, this statement strives to optimize hypertension treatment within the Chinese medical community.